Skip to main content
Clinical Trials/CTRI/2023/03/051129
CTRI/2023/03/051129
Not yet recruiting
Phase 2

Comparative Evaluation of Advanced Platelet Rich Fibrin Plus and Enamel Matrix Derivative In The Treatment of Periodontal Intrabony Defects: A Randomized Clinical Trial

OT APPLICABLE0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
OT APPLICABLE
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Stage II or III Periodontitis.
  • Systemically healthy patient.
  • good level of oral hygiene with Full\-Mouth Bleeding Score \<20% and Full
  • Mouth Plaque Index Score \<20%
  • presence of a minimum one or more 2\-, 3\-, or combined 2â??3\-wall intrabony
  • defect with a defect angle of 20â??40 (±5\) degrees
  • Pocket depths \>\= 6mm measured with UNC 15 probe.
  • Vertical bone loss \>\= 4mm seen on intraoral periapical radiograph.
  • No history of periodontal therapy in the preceding 6months.
  • No use of antibiotics in the preceding 6months which can interfere with bone healing.

Exclusion Criteria

  • With known systemic illness such as Diabetes mellitus, arthritis and osteoporosis.
  • Patients on systemic medications such as corticosteroids or Calcium channel blockers or taking long\-term NSAIDS or taking bisphosphonates
  • or calcium supplements.
  • Use of tobacco in any form and alcohol.
  • Teeth with Grade\-III mobility and/or furcation involvement.
  • Immunocompromised individuals.
  • Pregnant or lactating females.
  • Tooth with hopeless prognosis.
  • Non\-vital tooth with or without periapical pathology.
  • History of radiotherapy therapy in the preceding 1 year in head and neck region.

Outcomes

Primary Outcomes

Not specified

Similar Trials